Obesity is a growing public health concern, with 37.5% of the adult population in need of therapeutics that are more efficacious with a better side effect profile. An innovative target in this regard is neuromedin U, a neuropeptide shown to suppress food intake and attenuate weight gain in animal models. These effects of neuromedin U on feeding behavior are thought to be related to agonism at the centrally expressed neuromedin U receptor 2 (NMUR2). As peptides present unique challenges that limit their therapeutic potential, the discovery of small-molecule NMUR2 agonists is needed to validate the targets therapeutic value, but to date, none have been evaluated in any animal model of disease. We therefore assessed two smallmolecule NMUR2 agonists for their in vitro signaling and their in vivo efficacy. The NMUR2 agonists were synthesized and both NMUR2 agonists, NY0116 and NY0128, decreased cAMP while stimulating calcium signaling in stably expressing NMUR2 HEK293 cells. When small-molecule NMUR2 agonists were tested in vivo, acute administration significantly decreased high-fat diet consumption. Repeated administration of the compounds decreased body weight and more specifically, decreased the percentage of visceral adipose tissue (VAT) in obese mice. These results have confirmed small-molecule NMUR2 agonists are efficacious in animal models to decrease fat content, food intake, and body weight, suggesting NMUR2 is a promising therapeutic target for metabolic disorders. --
| INTRODUCTION
Obesity remains a troubling health problem that demands a more mechanistic appreciation of the molecular and neural basis of food consumption. 1 The complex nature of obesity, a disorder partially characterized by overconsumption of energy-dense foods, creates challenges for developing therapeutics. 2 Although 80 million people in the United States are obese, 3 the available medications and surgical interventions suffer from modest efficacy and/or numerous side effects. 4 Our objective is to identify and validate new druggable targets via pharmacological approaches that exploit an enhanced understanding of mechanisms underlying feeding behavior. Neuromedin U (NMU) is a neuropeptide, synthesized in the lateral hypothalamus and expressed in all mammals. 5 NMU-deficient mice are hyperphagic, obese, and have decreased metabolic activity. 6 Conversely, systemic administration of NMU peptide suppresses food intake 7 and causes weight loss. 8 NMU gene variants have also been associated with obesity, 9 whereas studies have also shown NMU to be upregulated in calorie restricted animals. 10 Together, these data suggest that NMU plays an important role in regulation of feeding and body weight.
To leverage the desirable antiobesity effects of NMU, it is important to understand the primary sites of action for NMU. There are two high-affinity receptors for NMU, neuromedin U receptor 1 (NMUR1) and NMUR2. These receptors also bind the endogenous neuropeptide neuromedin S (NMS). NMUR1 is enriched in the periphery, and may be involved in regulation of the immune system and responses to pain. 11, 12 NMUR2, however, is enriched in the brain, specifically the hypothalamus, confirmed by qRT-PCR and mRNA analyses. [13] [14] [15] NMUR2 is highly expressed in regions associated with food reward 16 and mediates the central effects of NMU (and NMS) on food intake and body weight. 8, 17 NMUR2 may represent a druggable target and a potential access point for the control of important neural pathways underlying food intake and ultimately obesity. NMUR2 is a G-proteincoupled receptor, suggested to couple to both G i/o and G q and was de-orphaned over 10 years ago. 7, 18 Following the discovery that NMUR2 (aka FM-4, TGR-1) is stimulated by NMU, NMUR2 was shown to play an important role in regulating food intake and body weight. Knockout of NMUR2 in mice causes hyperphagia, weight gain, and decreased metabolic activity. 17 Although not all studies observed the same effect on food intake after NMUR2 knockout. 8 Furthermore, our laboratory discovered that NMUR2 regulates specific types of feeding behavior in animal models. That is, knockdown of NMUR2 in the paraventricular nucleus of the hypothalamus potentiates binge-type eating, increases consumption of a highfat diet, and stimulates weight gain. 19 Recent studies have also
shown that NMU administered to the paraventricular nucleus of the hypothalamus also decreases intake 20 and motivation for highfat diet. 5 Taken together, NMUR2 activation shows therapeutic promise for treating obesity.
Several small-molecule agonists for NMUR2 were discovered by Meng et al. 21 via a high-throughput screen. A series of the original compounds were investigated in live-cell assays, allowing a preliminary structure-activity relationship. In particular, two structurally similar compounds, NY0116 and NY0128 (chemical structures shown in Figure 1A ) containing a lipophilic trityl motif and a hydrophilic guanidine scaffold were demonstrated as agonists against human NMUR1
(hNMUR1) and human NMUR2 (hNMUR2) via intracellular calcium mobilization assays. 21 
| MATERIALS AND METHODS

| Ethics statement
All experiments were carried out in accordance with all national and local guidelines and regulations, with the Guide for the Care and Use of Laboratory Animals 27, and with the approval of the Institutional Animal Care and Use Committee at The University of Texas Medical
Branch. All efforts were made to minimize animal suffering and to reduce the number of animals used.
| Compounds
NY0116 and NY0128 were synthesized in-house following a reported synthetic route 21 with optimized procedures. The chemical structures were fully characterized using H1 and C13 NMR and mass spectrometry techniques, and compound purity was verified using HPLC analysis. 
| Cell culture
| Tango beta-arrestin activity assay
The tango beta-arrestin assay was performed according to previously 
| 24-hour food intake
Male Sprague-Dawley rats (Harlan Laboratories Inc., Houston, TX)
were used, weighing 225-250g at the start of the experiments. The rats were single-housed in colony rooms maintained at 21.67°C and 30%-50% relative humidity with a 12-hour light-dark cycle (lights on 6:00 AM-6:00 PM) and allowed to habituate for 7 days. Rats were fed a standard (lean) diet (n = 40) (Teklad Mouse/Rat Diet 7912; Harlan Laboratories Inc., Houston, TX) or high-fat diet (n = 34) (45% kcal from fat; Open Source Diets formula D12451; Research Diets Inc., New Brunswick, NJ, USA) ad libitum, handled daily, and weighed every 3 days with a dynamic weighing apparatus (Ohaus Corp, Parsippany, NJ). To monitor intake, food hoppers were weighed every other day for 7 days. Two days before compound administration, rats were given a subcutaneous 2 mL/kg saline injection 1 hour before the onset of the dark cycle, which was repeated the next day. On the seventh day, food hoppers were removed and weighed before the rats received a subcutaneous injection of saline, NY0116, or NY0128 1 hour before the onset of the dark cycle. Hoppers were weighed 2, 4, 8, and 24 hours postinjection.
| Repeated compound administration
64 male diet induced obese (DIO) C57BL/6J mice age 18 weeks and 8 age matched C57BL/6 control mice (The Jackson Laboratories, Bar
Harbor, ME) were single-housed as described above and allowed to habituate for 14 days prior to experimentation. DIO mice were maintained on a high-fat diet (cat no. D12451, 45% energy from fat;
Open Source Diets formula D12451; Research Diets Inc., New Brunswick, NJ, USA) and control mice were maintained on a standard brown chow rodent diet, with access to food and water ad libitum. DIO mice have been maintained on a high-fat diet of at least 45% per kcal since weaning. 60 DIO mice were divided into seven treatment groups with one saline control group (n = 12), 3 NY0116 dose groups (3, 10, 30 mg/kg; n = 8/group), and 3 NY0128 dose groups (3, 10, 30 mg/kg; n = 8/group). Forty-eight hours prior to the start of the experiment, mice were given daily saline injections to allow them to acclimate to injections. Mice were then randomly divided into five groups (n = 12) that consisted of animals from each treatment group, with the first group beginning treatment on a Sunday and the fifth group beginning treatment on a Thursday, with all groups ending 14 days later on their respective days of the week.
Reasoning for the varied start is due to the time limitations of the micro-CT and the number of animals that can be scanned per day.
Daily doses began at 3 PM Central Standard Time (CST) and ended before the dark cycle began at 6 PM CST. Food intake, injections, and weight loss were recorded following a repeated measures design. Injection volumes were determined using the weight recorded 1 day prior to the start of treatment and re-evaluated and adjusted after day 7 treatment administration.
| Micro-CT scan
Mouse whole-body scans were performed using a Siemens Inveon 
| Serum collection
Post micro-CT scan, mice were exposed to CO 2 and decapitated.
Following decapitation, 500 μL of trunk blood was collected and allowed to incubate at room temp for >15 minutes. Following incubation, the blood samples were then centrifuged at 1500 g for 15 minutes. Following centrifugation, plasma was removed from the sample and the serum was stored at −80°C until further analysis.
Serum analysis was conducted by the Texas A&M Veterinary Medicine Diagnostic Laboratory. Cholesterol, creatinine, blood urea nitrogen, aspartate aminotransferase, and alanine aminotransferase and glucose levels were analyzed in the serum. Due to hemolysis of samples, some samples were unable to be accurately analyzed and were removed from further analysis.
| Data analysis and statistics
All data were analyzed using GraphPad Prism 7.0 software (La Jolla, CA 3 | RESULTS
| NMUR2 agonists NY0116 and NY0128 potently inhibit cAMP
The pharmacological activity of NMUR2 agonists NY0116 and NY0128 ( Figure 1A ) were evaluated in a G i mode cAMP assay using Figure 1C ) and 0.71 ± 1.36 nmol/L for NY0128 ( Figure 1D ) (Means ± SEM, n = 15-16 independent experiments) ( Table 1) . To validate the inhibition of cAMP by these NMUR2 agonists was G imediated, the stable NMUR2 expressing cells were pretreated with 150 ng/mL pertussis toxin for 18 hours to uncouple G i proteins. Pertussis toxin entirely reversed the observed cAMP inhibition, indicating the potent agonism of these ligands requires NMUR2-G i coupling ( Figure 1E ). To further insure the inhibition was due to activation of NMUR2, cells not expressing NMUR2 were also evaluated (Figure 1F) . There was no effect on cAMP at concentrations of compounds that decreased cAMP in the NMUR2 stably expressing cells. Figure 2A ). Robust responses to both ligands were observed indicating G q -mediated NMUR2 signaling. EC 50 values estimated from regression curves were 32.7 ± 1.1 μmol/L for NY0116 and 16.9 ± 0.9 μmol/L for NY0128 (Means ± SEM, n = 4). Although the observed potencies for both ligands were low, they are similar to the micromolar potencies previously reported for NMUR2 calcium signaling. 21 These calcium mobilization effects were not due to off-target compound activity as no significant increase in calcium mobilization was observed in wild-type HEK293 cells lacking the NMUR2 (Figure 2B ). In addition, vehicle treatment, with up to 0.5% DMSO (DMSO concentration at 100 μmol/L drug point), showed no effect on calcium mobilization in either NMUR2 stable or wild-type HEK293 cells.
As an additional functional assessment of NMUR2 signaling, the agonists were tested in a beta-arrestin recruitment and activity assay. Contrary to receptor-mediated G i /cAMP or G q /calcium signaling, NY0116 and NY0128 did not recruit beta-arrestin, even when the ligands were tested up to 10 μmol/L ( Figure 2C ). NY0128 also significantly decreased basal levels of beta-arrestin recruitment and activity, whereas NY0116 did not ( Figure 2D ) ( Table 2 ).
| Pharmacokinetics study
Plasma concentrations for NY0116 peak at 10 hours (n = 3 for all time points, except at 10 hours when n = 2) ( Figure 3A ). Plasma concentrations for NY0128 peak at 4 hours postinjection (n = 3 for all time points, except at 45 min when n = 2) ( Figure 3B ). According to Lipinski's "Rule of Five" for drug-like properties, 25 both compounds NY0116 and NY0128 have suitable physicochemical parameters (eg, cLogP = 3.37, tPSA = 71.13 for NY0116, and cLogP = 3.67, tPSA = 71.13 for NY0128 calculated by ChemBioDraw). Pharmacokinetic parameters for NY0116 and NY0128 determined by noncompartmental analysis ( Figure 3C ). Pharmacokinetic analysis of NY0116
( Figure 3D ) and NY0128 ( Figure 3E ) concentrations in rats' wholebrain homogenates and the brain-to-plasma ratio of NY0116
( Figure 3F ) and NY0128 ( Figure 3G ) shows that the compounds accumulate in the brain over time. 
| Acute NY0116 and NY0128 decrease food intake
We evaluated the effects of NY0116 and NY0128 on intake of a standard diet and a high-fat diet. NY0116 had no effect on consumption of a standard diet (main effect of drug treatment F (2,21) = 2.72, P = .09, effect of time F(3,63) = 1279, P < .001, and interaction F(6,63) = 1.67, P = .14) ( Figure 4A ). NY0116, however, inhibited intake of a high-fat diet (main effect of drug treatment F (2,19) = 2.47, P = .11, effect of time F(3,57) = 1279, P < .001, and interaction F(6,57) = 2.86, P = .016) over 24 hours vs vehicle controls ( Figure 4B ). Post hoc analysis revealed that this effect was not significant at the 2, 4, and 8 hour time points, but was significant at both 9 and 90 mg/kg after 24 hours of cumulative food intake.
For NY0128, a significant reduction in standard diet consumption was observed (main effect of drug treatment F(2,22) = 8.64, P = .002, effect of time F(3,66) = 1007, P < .001, and interaction F (6,66) = 3.20, P = .008), an effect which was pronounced in both the 3 and 30 mg/kg treatments at the 8-hour and 24-hour time points ( Figure 4C ). NY0128 also suppressed intake of a high-fat diet in a 
| Repeated NY0116 and NY0128 decrease bodyweight, VAT, and cholesterol on a high-fat diet
Compounds were administered over 14 days at doses of 3, 10, and 30 mg/kg. Both NY0116 and NY0128 treatments significantly decreased bodyweight (F(5,42) = 10.69, P < .001) compared to vehicle, whereas mice were maintained on a high-fat diet ( Figure 5A-B) .
To compare the amounts of VAT between the groups, 23 we examined the cross section at the L5 vertebrae, using Inveon Research Workplace for quantification. Representative images of the cross sections quantified are shown in Figure 5C . There was a significant main effect (F(5,44) = 26.86, P < .001) and the high dose of NY0128 significantly decreased VAT percentage compared to vehicle ( Figure 5D ). Food intake was measured daily with no significant effect seen during the study ( Figure 5E ). Serum chemistry analysis showed a significant decrease (F(7,45) = 32.48, P < .001) in cholesterol ( Figure S1 ) at the highest dose of NY0128, with no change in blood urea nitrogen (BUN) ( Figure S1 ). There were also no observed drug-induced changes in creatinine and aspartate aminotransferase (AST) ( Figure S1 ).
| DISCUSSION
In this study, we evaluated the potency and efficacy of two small 
| CONCLUSION
We provide strong evidence that two small-molecule agonists for NMUR2 activate both G i -mediated cAMP inhibition and G q -mediated calcium signaling, achieve appreciable brain levels after a single subcutaneous dose, and decrease high-fat diet intake in rats. Although NY0116 and NY0128 are not selective for NMUR2 (also act on NMUR1), our laboratory and others have demonstrated that NMUR2 in particular is a key regulator of feeding behavior, 7, 19, 30 and therefore the likely target for these agonists. Furthermore, despite being fed a high-fat diet, repeated administration of NY0128 reduces body weight, VAT, and cholesterol in obese mice. Although the NMUR2 agonists presented here require further optimization, these small molecules demonstrate promising effects as lead drug candidates on feeding, fat content and body weight composition. Taken together, this work indicates NMUR2 agonism has pharmacotherapeutic potential for addressing metabolic disorders, such as obesity.
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